Voltage-gated sodium channel inhibitor reduces atherosclerosis by modulating monocyte/macrophage subsets and

Haiying Sun1, Jipeng Jiang2, Lei Gong3

  • 1Graduate School, Tianjin Medical University, Qixiangtai Road No. 22, Tianjin 300070, China; Institute of Cardiovascular Disease and Heart Center, Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Chinese People's Armed Police Force (PAP) Medical Center, Chenglin Road No. 220, Hedong District, Tianjin 300162, China.

Insights

Blocking voltage-gated sodium channels (VGSCs) in monocytes and macrophages reduces atherosclerosis. This approach modulates immune cell subsets and suppresses macrophage proliferation, offering potential cardiovascular protection.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Cell Biology

Background:

  • Inflammatory monocyte and macrophage accumulation exacerbates atherosclerosis.
  • Voltage-gated sodium channels (VGSCs) regulate monocyte/macrophage functions.
  • Modulating these channels may offer atheroprotective effects.

Purpose of the Study:

  • To investigate if blocking VGSCs in mononuclear phagocytes is atheroprotective.
  • To determine the effects on monocyte/macrophage subsets and proliferation in atherosclerotic lesions.

Main Methods:

  • In vitro studies: RNA interference knockdown of VGSCs in mouse monocytes and RAW264.7 cells.
  • In vivo studies: ApoE knockout mice fed Western diet, treated with phenytoin (PHT).
  • Assessed cell proliferation, migration, polarization (M1/M2), plasma lipids, and atherosclerotic plaque size.

Main Results:

  • In vitro: VGSC knockdown reduced RAW264.7 cell proliferation, migration, and phagocytosis.
  • In vitro: Suppressed M1 polarization and promoted M2 polarization.
  • In vivo: PHT treatment elevated anti-inflammatory phenotypes, reduced pro-inflammatory phenotypes, suppressed macrophage proliferation, and decreased atherosclerotic plaques without altering plasma lipids.

Conclusions:

  • Blockade of VGSCs in mononuclear phagocytes reduces atherosclerotic lesions.
  • This effect is mediated by altering monocyte/macrophage subsets and suppressing macrophage proliferation.
  • VGSC blockade shows potential for cardiovascular protection.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
Inflammation01:38

Inflammation

Overview
61.4K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
738
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.7K